Brand Reference: Avodart
| Metric | Verified Benchmark | Source |
|---|---|---|
| Dutasteride RxNorm Concept ID | 228790 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1350 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $98.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $7.90 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $11.00 / mo | 34 Zero-PHI Verified Patient Logs |
Inhibits both sebaceous/dermal Type I and follicular/prostatic Type II 5-alpha-reductase with 45x greater Type I and 2.5x greater Type II potency than finasteride—suppressing serum DHT by >93% and scalp DHT by ~51% vs ~41% on finasteride.
For self-pay patients filling Dutasteride (NDC 00378-4650-93), direct wholesale and telehealth fulfillment drops monthly spend from $98.00 retail to $7.90 (92% savings against a $0.1350 CMS pharmacy acquisition baseline).
Clinical clearance of Dutasteride (Dual Type I, II & III 5-Alpha-Reductase Pan-Inhibitor) relies on hepatic cyp3a4 and cyp3a5 hydroxylation; fecal elimination with a ~5 weeks (35 days steady-state depot) half-life; patients absorbing at 60% softgel oral bioavailability typically observe target onset around 1–2 weeks >85% dht suppression; 4–6 months vertex density gain.
FDA clinical labeling for Dutasteride restricts administration in pregnancy / women of childbearing potential; blood donation prohibited for 6 months after last capsule across 0.5 mg PO 2–3x weekly (intermittent alopecia protocol), 0.5 mg PO once daily, with self-reported patient tracking dominated by dry scalp sebum reduction (9% of reports), libido attenuation (7% of reports), breast tenderness (3% of reports).
Across 34 verified cash-pay logs, Dutasteride achieves a 90.20% Worth-It rating with out-of-pocket spend averaging $11.00/mo versus $98.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 0.5 mg PO 2–3x weekly (intermittent alopecia protocol) for Dutasteride; monthly out-of-pocket dropped to $6.95 compared with $98.00 retail.
Completed 10 weeks on Dutasteride (0.5 mg PO once daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 0.5 mg PO 2–3x weekly (intermittent alopecia protocol) Dutasteride sourced via TeleMed ($9.16/mo cash pay without insurance prior authorization).